| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 46 | 2024 | 262 | 10.800 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 42 | 2024 | 199 | 8.400 |
Why?
|
| Connective Tissue Diseases | 16 | 2024 | 70 | 4.180 |
Why?
|
| Autoimmune Diseases | 10 | 2017 | 250 | 2.660 |
Why?
|
| Pyridones | 6 | 2024 | 56 | 2.020 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2024 | 2677 | 2.000 |
Why?
|
| Pulmonary Fibrosis | 9 | 2023 | 138 | 1.950 |
Why?
|
| Alveolitis, Extrinsic Allergic | 7 | 2024 | 42 | 1.930 |
Why?
|
| Indoles | 6 | 2024 | 301 | 1.760 |
Why?
|
| Respiration Disorders | 2 | 2022 | 41 | 1.440 |
Why?
|
| Bronchiectasis | 3 | 2017 | 15 | 1.430 |
Why?
|
| Occupational Exposure | 2 | 2022 | 87 | 1.420 |
Why?
|
| Occupational Health | 2 | 2021 | 36 | 1.380 |
Why?
|
| Immunosuppressive Agents | 9 | 2023 | 979 | 1.260 |
Why?
|
| Idiopathic Interstitial Pneumonias | 6 | 2022 | 28 | 1.250 |
Why?
|
| Asthma | 6 | 2019 | 984 | 1.210 |
Why?
|
| Lung | 20 | 2024 | 1292 | 1.170 |
Why?
|
| Precision Medicine | 2 | 2023 | 413 | 1.130 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2022 | 171 | 1.110 |
Why?
|
| Humans | 108 | 2024 | 89985 | 1.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 244 | 1.030 |
Why?
|
| Aged | 51 | 2024 | 19262 | 1.030 |
Why?
|
| Registries | 7 | 2024 | 808 | 1.010 |
Why?
|
| Respiratory Function Tests | 11 | 2021 | 140 | 0.940 |
Why?
|
| Autoimmunity | 6 | 2018 | 169 | 0.930 |
Why?
|
| Sjogren's Syndrome | 3 | 2021 | 34 | 0.900 |
Why?
|
| Male | 70 | 2024 | 42690 | 0.890 |
Why?
|
| Middle Aged | 46 | 2024 | 26159 | 0.850 |
Why?
|
| Disease Progression | 16 | 2023 | 1469 | 0.840 |
Why?
|
| Female | 62 | 2024 | 46602 | 0.830 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2021 | 6 | 0.770 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2019 | 78 | 0.770 |
Why?
|
| Retrospective Studies | 28 | 2024 | 9216 | 0.750 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 124 | 0.740 |
Why?
|
| Survival Analysis | 6 | 2024 | 1497 | 0.740 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 31 | 0.730 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2016 | 17 | 0.690 |
Why?
|
| Bronchial Thermoplasty | 1 | 2019 | 6 | 0.680 |
Why?
|
| Hernia, Hiatal | 2 | 2018 | 38 | 0.680 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 212 | 0.660 |
Why?
|
| Prevalence | 9 | 2021 | 1250 | 0.630 |
Why?
|
| Aspergillus | 2 | 2017 | 9 | 0.630 |
Why?
|
| Hospitalization | 3 | 2021 | 888 | 0.620 |
Why?
|
| Cohort Studies | 17 | 2024 | 2886 | 0.620 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 3 | 2017 | 7 | 0.600 |
Why?
|
| Tacrolimus | 2 | 2017 | 369 | 0.600 |
Why?
|
| Esophagus | 1 | 2018 | 107 | 0.590 |
Why?
|
| Azathioprine | 2 | 2023 | 124 | 0.580 |
Why?
|
| Biological Products | 1 | 2019 | 161 | 0.560 |
Why?
|
| Proteomics | 5 | 2024 | 232 | 0.560 |
Why?
|
| Antifungal Agents | 2 | 2014 | 123 | 0.530 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 586 | 0.520 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 644 | 0.520 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 344 | 0.520 |
Why?
|
| Scleroderma, Systemic | 4 | 2023 | 53 | 0.490 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2014 | 4 | 0.480 |
Why?
|
| Lung Transplantation | 6 | 2024 | 313 | 0.480 |
Why?
|
| Referral and Consultation | 3 | 2024 | 345 | 0.470 |
Why?
|
| Telomere | 5 | 2023 | 119 | 0.470 |
Why?
|
| Prognosis | 13 | 2024 | 3800 | 0.470 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 344 | 0.470 |
Why?
|
| Diagnosis, Differential | 9 | 2024 | 1606 | 0.460 |
Why?
|
| Prospective Studies | 11 | 2024 | 4329 | 0.460 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2020 | 346 | 0.450 |
Why?
|
| Vital Capacity | 6 | 2022 | 69 | 0.430 |
Why?
|
| Biomarkers | 7 | 2024 | 1778 | 0.420 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1732 | 0.410 |
Why?
|
| Muscle, Smooth | 6 | 1996 | 355 | 0.410 |
Why?
|
| Sputum | 1 | 2012 | 35 | 0.410 |
Why?
|
| Adult | 21 | 2023 | 26827 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1055 | 0.400 |
Why?
|
| Biopsy | 4 | 2022 | 1184 | 0.390 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2017 | 270 | 0.390 |
Why?
|
| United States | 12 | 2024 | 7114 | 0.390 |
Why?
|
| Self Care | 1 | 2012 | 166 | 0.380 |
Why?
|
| Dermatomyositis | 4 | 2019 | 18 | 0.360 |
Why?
|
| Muscle Contraction | 6 | 1996 | 286 | 0.350 |
Why?
|
| Mucin-5B | 3 | 2019 | 12 | 0.330 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 460 | 0.330 |
Why?
|
| Myositis | 2 | 2020 | 18 | 0.320 |
Why?
|
| Bronchodilator Agents | 3 | 2017 | 66 | 0.310 |
Why?
|
| Treatment Outcome | 10 | 2024 | 8277 | 0.310 |
Why?
|
| Trachea | 5 | 1996 | 292 | 0.290 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 1691 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 387 | 0.280 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 848 | 0.280 |
Why?
|
| Time Factors | 6 | 2024 | 5358 | 0.280 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 358 | 0.280 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1862 | 0.270 |
Why?
|
| Acetylcysteine | 2 | 2018 | 71 | 0.270 |
Why?
|
| Fibrosis | 4 | 2022 | 236 | 0.260 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2018 | 0.250 |
Why?
|
| Environmental Exposure | 2 | 2019 | 334 | 0.240 |
Why?
|
| Quality of Life | 4 | 2023 | 1682 | 0.240 |
Why?
|
| Hypothyroidism | 2 | 2016 | 243 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 366 | 0.220 |
Why?
|
| Telomerase | 2 | 2020 | 67 | 0.210 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 51 | 0.210 |
Why?
|
| Emphysema | 1 | 2023 | 23 | 0.210 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 37 | 0.210 |
Why?
|
| Phenotype | 5 | 2020 | 2457 | 0.210 |
Why?
|
| Mediastinum | 2 | 2019 | 47 | 0.200 |
Why?
|
| Patient Compliance | 2 | 2020 | 230 | 0.200 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 26 | 0.200 |
Why?
|
| Machine Learning | 1 | 2024 | 270 | 0.190 |
Why?
|
| Acetylcholine | 5 | 1996 | 177 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 147 | 0.190 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 22 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.190 |
Why?
|
| Polymyositis | 2 | 2013 | 6 | 0.190 |
Why?
|
| Survival Rate | 5 | 2020 | 1899 | 0.190 |
Why?
|
| Leukotriene Antagonists | 1 | 2001 | 25 | 0.190 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 84 | 0.190 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 983 | 0.180 |
Why?
|
| Blood Proteins | 2 | 2024 | 149 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 86 | 0.180 |
Why?
|
| Hematology | 1 | 2020 | 30 | 0.180 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 133 | 0.170 |
Why?
|
| Peroxidase | 2 | 2019 | 51 | 0.170 |
Why?
|
| Societies | 1 | 2019 | 16 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 855 | 0.170 |
Why?
|
| Fever | 1 | 2020 | 127 | 0.170 |
Why?
|
| Sexism | 1 | 2020 | 54 | 0.170 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 52 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 192 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 34 | 0.170 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 276 | 0.170 |
Why?
|
| Aging | 1 | 2024 | 727 | 0.170 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 6785 | 0.160 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2021 | 2327 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2021 | 275 | 0.160 |
Why?
|
| Risk Factors | 5 | 2021 | 5562 | 0.160 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 84 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2019 | 100 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 2 | 2018 | 125 | 0.150 |
Why?
|
| Eosinophils | 3 | 1993 | 194 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2019 | 550 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2023 | 556 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 2360 | 0.150 |
Why?
|
| Logistic Models | 2 | 2019 | 1214 | 0.150 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 59 | 0.150 |
Why?
|
| Propensity Score | 1 | 2018 | 149 | 0.140 |
Why?
|
| Observer Variation | 2 | 2017 | 614 | 0.140 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.140 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 218 | 0.140 |
Why?
|
| Cause of Death | 1 | 2018 | 269 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2017 | 958 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 237 | 0.140 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 34 | 0.140 |
Why?
|
| Radiography | 2 | 2016 | 808 | 0.140 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 24 | 0.140 |
Why?
|
| Prednisone | 1 | 2017 | 255 | 0.140 |
Why?
|
| Clinical Studies as Topic | 1 | 2016 | 4 | 0.140 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 2370 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 107 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 64 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 102 | 0.130 |
Why?
|
| Granuloma | 1 | 2016 | 65 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 146 | 0.130 |
Why?
|
| Total Lung Capacity | 1 | 2016 | 5 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.130 |
Why?
|
| Transcriptome | 1 | 2021 | 661 | 0.130 |
Why?
|
| Polylysine | 1 | 1996 | 34 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 141 | 0.130 |
Why?
|
| Leukocytes | 3 | 2023 | 209 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 405 | 0.130 |
Why?
|
| Phospholipases A | 2 | 1993 | 45 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2010 | 357 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 387 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Ribonucleases | 1 | 1996 | 93 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 176 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 323 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2018 | 679 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 468 | 0.120 |
Why?
|
| Radiography, Thoracic | 2 | 2018 | 324 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 1929 | 0.120 |
Why?
|
| Antigens | 1 | 2016 | 229 | 0.120 |
Why?
|
| Pulmonary Medicine | 1 | 2015 | 46 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 952 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 162 | 0.120 |
Why?
|
| Guinea Pigs | 5 | 1996 | 172 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 266 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 365 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1134 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2769 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 422 | 0.110 |
Why?
|
| Antifibrinolytic Agents | 1 | 2014 | 39 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 785 | 0.110 |
Why?
|
| Macrolides | 1 | 2013 | 30 | 0.110 |
Why?
|
| Phenylpropionates | 1 | 2013 | 7 | 0.110 |
Why?
|
| Adalimumab | 1 | 2014 | 89 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 437 | 0.110 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2013 | 9 | 0.110 |
Why?
|
| Pyridazines | 1 | 2013 | 21 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 953 | 0.110 |
Why?
|
| Bronchi | 2 | 2013 | 230 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2013 | 82 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 2013 | 72 | 0.110 |
Why?
|
| Airway Management | 1 | 2013 | 46 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1082 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1545 | 0.100 |
Why?
|
| Chicago | 1 | 2017 | 1434 | 0.100 |
Why?
|
| Peptides | 1 | 1996 | 649 | 0.100 |
Why?
|
| Canada | 2 | 2023 | 208 | 0.100 |
Why?
|
| Societies, Medical | 3 | 2024 | 584 | 0.100 |
Why?
|
| Serotonin | 1 | 1993 | 221 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 1131 | 0.100 |
Why?
|
| Child | 1 | 2023 | 7242 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 264 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 203 | 0.090 |
Why?
|
| Voriconazole | 1 | 2010 | 18 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2015 | 948 | 0.090 |
Why?
|
| In Vitro Techniques | 5 | 1996 | 996 | 0.090 |
Why?
|
| Pregnancy | 1 | 2017 | 3046 | 0.090 |
Why?
|
| Young Adult | 3 | 2017 | 6415 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 145 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1452 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1866 | 0.080 |
Why?
|
| Triazoles | 1 | 2010 | 104 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 135 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 200 | 0.080 |
Why?
|
| Europe | 2 | 2023 | 324 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2657 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 798 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1396 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 371 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 754 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 264 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 8 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 889 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2314 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 30 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 156 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 19 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 26 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 29 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2023 | 93 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1714 | 0.050 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.050 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2003 | 9 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 20 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 146 | 0.050 |
Why?
|
| Antacids | 1 | 2022 | 4 | 0.050 |
Why?
|
| North America | 1 | 2023 | 188 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2019 | 1380 | 0.050 |
Why?
|
| Cough | 1 | 2022 | 55 | 0.050 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2021 | 26 | 0.050 |
Why?
|
| Pulmonologists | 1 | 2021 | 7 | 0.050 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.050 |
Why?
|
| Radiologists | 1 | 2021 | 50 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2001 | 48 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 126 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 366 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 52 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 15 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 118 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 352 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 3 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Animals | 8 | 2017 | 27536 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 4 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 9 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 67 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 84 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 408 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 143 | 0.040 |
Why?
|
| Rheumatology | 1 | 2019 | 35 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 189 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 165 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 326 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 58 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 355 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 399 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 40 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 3404 | 0.030 |
Why?
|
| Microscopic Angioscopy | 1 | 2016 | 1 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 103 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1075 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 278 | 0.030 |
Why?
|
| Cytochalasin B | 2 | 1993 | 19 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 1993 | 34 | 0.030 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 39 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 371 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 450 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 147 | 0.030 |
Why?
|
| Eosinophil Granule Proteins | 1 | 1996 | 20 | 0.030 |
Why?
|
| Cations | 1 | 1996 | 30 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 39 | 0.030 |
Why?
|
| Atropine | 1 | 1996 | 60 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 961 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 16 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 1993 | 44 | 0.030 |
Why?
|
| Acetophenones | 2 | 1993 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 869 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1731 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1913 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 48 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 490 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 981 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 583 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 206 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2887 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 591 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 327 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 657 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 270 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 485 | 0.030 |
Why?
|
| Blood Cells | 1 | 1993 | 33 | 0.030 |
Why?
|
| Kinetics | 2 | 1993 | 1534 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1993 | 19 | 0.030 |
Why?
|
| Phenyl Ethers | 1 | 1993 | 13 | 0.030 |
Why?
|
| Acetamides | 1 | 1993 | 26 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 693 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1993 | 93 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 137 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1993 | 90 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 94 | 0.030 |
Why?
|
| 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine | 1 | 1992 | 4 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 667 | 0.030 |
Why?
|
| Advance Care Planning | 1 | 2013 | 45 | 0.030 |
Why?
|
| Eicosanoids | 1 | 1992 | 16 | 0.030 |
Why?
|
| Receptors, Muscarinic | 1 | 1992 | 48 | 0.030 |
Why?
|
| Epithelium | 1 | 1993 | 323 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2016 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1992 | 77 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 281 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1993 | 365 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 44 | 0.020 |
Why?
|
| Terminal Care | 1 | 2013 | 137 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1991 | 53 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 1991 | 90 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 503 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3253 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 778 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2395 | 0.020 |
Why?
|
| Body Water | 1 | 1989 | 35 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1989 | 56 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 1989 | 48 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 437 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 4169 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1983 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2415 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 671 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Carboxylic Acids | 1 | 2006 | 17 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2006 | 126 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 11858 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3678 | 0.010 |
Why?
|
| Leukotriene C4 | 1 | 1993 | 21 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 1993 | 66 | 0.010 |
Why?
|
| Quinacrine | 1 | 1993 | 14 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1993 | 14 | 0.010 |
Why?
|
| SRS-A | 1 | 1993 | 27 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1993 | 112 | 0.010 |
Why?
|
| Peroxidases | 1 | 1993 | 34 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1993 | 63 | 0.010 |
Why?
|
| Superoxides | 1 | 1993 | 74 | 0.010 |
Why?
|
| Cell Separation | 1 | 1993 | 199 | 0.010 |
Why?
|
| Tachyphylaxis | 1 | 1991 | 14 | 0.010 |
Why?
|
| Pyridinium Compounds | 1 | 1991 | 10 | 0.010 |
Why?
|
| Blood | 1 | 1991 | 69 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 312 | 0.010 |
Why?
|
| Homeostasis | 1 | 1993 | 418 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 198 | 0.010 |
Why?
|
| Perfusion | 1 | 1991 | 253 | 0.010 |
Why?
|
| Respiratory System | 1 | 1989 | 117 | 0.000 |
Why?
|
| Dogs | 1 | 1989 | 706 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 4048 | 0.000 |
Why?
|